Patents by Inventor Pradip Mukerji
Pradip Mukerji has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 8916361Abstract: The subject invention relates to the identification of a gene involved in the elongation of polyunsaturated fatty acids containing unsaturation at the carbon 9 position (i.e., “?9-elongase”) and to uses thereof. In particular, ?9-elongase may be utilized, for example, in the conversion of linoleic acid (LA, 18:2n-6) to eicosadienoic acid (EDA, 20:2n-6). The production of dihomo-?-linolenic acid (DGLA, 20:3n-6) from eicosadienoic acid (EDA, 20:2n-6), and arachidonic acid (AA, 20:4n-6) from dihomo-?-linolenic acid (DGLA, 20:3n-6) is then catalyzed by ?8-desaturase and ?5-desaturase, respectively. AA or polyunsaturated fatty acids produced therefrom may be added to pharmaceutical compositions, nutritional compositions, animal feeds, as well as other products such as cosmetics.Type: GrantFiled: November 14, 2007Date of Patent: December 23, 2014Assignee: Abbott LaboratoriesInventors: Tapas Das, Pradip Mukerji, Padmavathy Krishnan, Amanda E. Leonard, Suzette L. Pereira
-
Patent number: 8916154Abstract: Disclosed are antibodies that specifically recognize ?5-desaturase, methods of producing the antibodies, nucleotides and polypeptides for producing the antibodies, and methods of using the antibodies. The ?5-desaturase-specific antibodies provide improved methods of detecting ?5-desaturase in a sample.Type: GrantFiled: January 13, 2010Date of Patent: December 23, 2014Assignee: Abbott LaboratoriesInventors: Tapas Das, Suzette L. Pereira, Pradip Mukerji, Padmavathy Krishnan
-
Patent number: 8796333Abstract: Disclosed are methods of treating an individual having a condition characterized by an imbalance in type 1 and type 2 cytokine production, wherein the method comprises administering to the individual an amount of ?-hydroxy-?-methylbutyrate (HMB) effective to modulate or otherwise cause an increase in the ratio of type 1 to type 2 cytokines, including an increase in the ratio of type 1 to type 2 cytokines without a corresponding increase in type 2 cytokine levels. Also disclosed are methods of using HMB to treat asthma and allergies. The methods of the present invention are based upon the discovery that HMB modulates cytokine production, most typically by increasing type 1 cytokines without a corresponding increase in type 2 cytokines.Type: GrantFiled: January 11, 2012Date of Patent: August 5, 2014Assignee: Abbott LaboratoriesInventors: Debra L. Thomas, Pradip Mukerji
-
Patent number: 8785495Abstract: The present invention relates to methods for the prevention and treatment of chronic inflammatory diseases, cancer, and involuntary weight loss. In the practice of the present invention patients are enterally administered HMB alone or alternatively in combination with eicosapentaenoic (20:5 ?-3), FOS, carnitine and mixtures thereof. HMB may be added to food products comprising a source of amino-nitrogen enriched with large neutral amino acids such as leucine, isoleucine, valine, tyrosine, threonine and phenylalanine and substantially lacking in free amino acids.Type: GrantFiled: January 11, 2012Date of Patent: July 22, 2014Assignee: Abbott LaboratoriesInventors: Jeffrey H. Baxter, Anne C. Voss, Pradip Mukerji
-
Patent number: 8785496Abstract: The present invention relates to methods for the prevention and treatment of chronic inflammatory diseases, cancer, and involuntary weight loss. In the practice of the present invention patients are enterally administered HMB alone or alternatively in combination with eicosapentaenoic (20:5 ?-3), FOS, carnitine and mixtures thereof. HMB may be added to food products comprising a source of amino-nitrogen enriched with large neutral amino acids such as leucine, isoleucine, valine, tyrosine, threonine and phenylalanine and substantially lacking in free amino acids.Type: GrantFiled: January 11, 2012Date of Patent: July 22, 2014Assignee: Abbott LaboratoriesInventors: Jeffrey H. Baxter, Anne C. Voss, Pradip Mukerji
-
Patent number: 8778632Abstract: The subject invention relates to the identification of genes involved in the desaturation of polyunsaturated fatty acids at carbon 6 (i.e., “?6-desaturase”). In particular, ?6-desaturase may be utilized, for example, in the conversion of linoleic acid to ?-linolenic acid and in the conversion of ?-linolenic acid stearidonic acid. The polyunsaturated fatty acids produced by use of the enzyme may be added to pharmaceutical compositions, nutritional compositions, animal feeds, as well as other products such as cosmetics.Type: GrantFiled: October 23, 2008Date of Patent: July 15, 2014Assignee: Abbott LaboratoriesInventors: Pradip Mukerji, Yung-Sheng Huang, Amanda E. Leonard, Suzette L. Pereira, Jennifer M. Thurmond
-
Patent number: 8778992Abstract: Disclosed are methods of treating an individual having a condition characterized by an imbalance in type 1 and type 2 cytokine production, wherein the method comprises administering to the individual an amount of ?-hydroxy-?-methylbutyrate (HMB) effective to modulate or otherwise cause an increase in the ratio of type 1 to type 2 cytokines, including an increase in the ratio of type 1 to type 2 cytokines without a corresponding increase in type 2 cytokine levels. Also disclosed are methods of using HMB to treat asthma and allergies. The methods of the present invention are based upon the discovery that HMB modulates cytokine production, most typically by increasing type 1 cytokines without a corresponding increase in type 2 cytokines.Type: GrantFiled: December 19, 2006Date of Patent: July 15, 2014Assignee: Abbott LaboratoriesInventors: Debra L. Thomas, Pradip Mukerji
-
Patent number: 8778993Abstract: The present invention relates to methods for the prevention and treatment of chronic inflammatory diseases, cancer, and involuntary weight loss. In the practice of the present invention patients are enterally administered HMB alone or alternatively in combination with eicosapentaenoic (20:5 ?-3), FOS, carnitine and mixtures thereof. HMB may be added to food products comprising a source of amino-nitrogen enriched with large neutral amino acids such as leucine, isoleucine, valine, tyrosine, threonine and phenylalanine and substantially lacking in free amino acids.Type: GrantFiled: January 11, 2012Date of Patent: July 15, 2014Assignee: Abbott LaboratoriesInventors: Jeffrey H. Baxter, Anne C. Voss, Pradip Mukerji
-
Patent number: 8778994Abstract: The present invention relates to methods for the prevention and treatment of chronic inflammatory diseases, cancer, and involuntary weight loss. In the practice of the present invention patients are enterally administered HMB alone or alternatively in combination with eicosapentaenoic (20:5 ?-3), FOS, carnitine and mixtures thereof. HMB may be added to food products comprising a source of amino-nitrogen enriched with large neutral amino acids such as leucine, isoleucine, valine, tyrosine, threonine and phenylalanine and subtantially lacking in free amino acids.Type: GrantFiled: January 11, 2012Date of Patent: July 15, 2014Assignee: Abbott LaboratoriesInventors: Jeffrey H. Baxter, Anne C. Voss, Pradip Mukerji, Michael J. Tisdale
-
Patent number: 8722384Abstract: The present invention relates to fatty acid desaturases able to catalyze the conversion of oleic acid to linoleic acid, linoleic acid to ?-linolenic acid, or of alpha-linolenic acid to stearidonic acid. Nucleic acid sequences encoding desaturases, nucleic acid sequences which hybridize thereto, DNA constructs comprising a desaturase gene, and recombinant host microorganism or animal expressing increased levels of a desaturase are described. Methods for desaturating a fatty acid and for producing a desaturated fatty acid by expressing increased levels of a desaturase are disclosed. Fatty acids, and oils containing them, which have been desaturated by a desaturase produced by recombinant host microorganisms or animals are provided. Pharmaceutical compositions, infant formulas or dietary supplements containing fatty acids which have been desaturated by a desaturase produced by a recombinant host microorganism or animal also are described.Type: GrantFiled: March 30, 2009Date of Patent: May 13, 2014Assignees: Calgene LLC, Abbott LaboratoriesInventors: Deborah Knutzon, Pradip Mukerji, Yung-Sheng Huang, Jennifer Thurmond, Sunita Chaudhary, Amanda Eun-Yeong Leonard
-
Patent number: 8609725Abstract: The present invention relates to methods for the prevention and treatment of chronic inflammatory diseases, cancer, and involuntary weight loss. In the practice of the present invention patients are enterally administered HMB alone or alternatively in combination with eicosapentaenoic (20:5 ?-3), FOS, carnitine and mixtures thereof. HMB may be added to food products comprising a source of amino-nitrogen enriched with large neutral amino acids such as leucine, isoleucine, valine, tyrosine, threonine and phenylalanine and substantially lacking in free amino acids.Type: GrantFiled: January 11, 2012Date of Patent: December 17, 2013Assignee: Abbott LaboratoriesInventors: Jeffrey H. Baxter, Anne C. Voss, Pradip Mukerji, Michael J. Tisdale
-
Publication number: 20130011498Abstract: The present invention relates to methods for the prevention and treatment of chronic inflammatory diseases, cancer, and involuntary weight loss. In the practice of the present invention patients are enterally administered HMB alone or alternatively in combination with eicosapentaenoic (20:5 ?-3), FOS, carnitine and mixtures thereof. HMB may be added to food products comprising a source of amino-nitrogen enriched with large neutral amino acids such as leucine, isoleucine, valine, tyrosine, threonine and phenylalanine and subtantially lacking in free amino acids.Type: ApplicationFiled: January 11, 2012Publication date: January 10, 2013Applicant: ABBOTT LABORATORIESInventors: Jeffrey H. Baxter, Anne C. Voss, Pradip Mukerji, Michael J. Tisdale
-
Patent number: 8247653Abstract: The present invention is related to isolated polynucleotides encoding a delta-8 desaturase, delta-8 desaturases encoded by the isolated polynucleotides, expression vectors containing the isolated polynucleotides, host cells containing the expression vectors and methods for producing delta-8 desaturases and polyunsaturated fatty acids.Type: GrantFiled: October 6, 2009Date of Patent: August 21, 2012Assignee: Abbott LaboratoriesInventors: Tapas Das, Pradip Mukerji, Padmavathy Krishnan, Suzette L. Pereira
-
Publication number: 20120196829Abstract: The present invention relates to methods for the prevention and treatment of chronic inflammatory diseases, cancer, and involuntary weight loss. In the practice of the present invention patients are enterally administered HMB alone or alternatively in combination with eicosapentaenoic (20:5 ?-3), FOS, carnitine and mixtures thereof. HMB may be added to food products comprising a source of amino-nitrogen enriched with large neutral amino acids such as leucine, isoleucine, valine, tyrosine, threonine and phenylalanine and substantially lacking in free amino acids.Type: ApplicationFiled: January 11, 2012Publication date: August 2, 2012Applicant: ABBOTT LABORATORIESInventors: Jeffrey H. Baxter, Anne C. Voss, Pradip Mukerji
-
Publication number: 20120189714Abstract: The present invention relates to methods for the prevention and treatment of chronic inflammatory diseases, cancer, and involuntary weight loss. In the practice of the present invention patients are enterally administered HMB alone or alternatively in combination with eicosapentaenoic (20:5 ?-3), FOS, carnitine and mixtures thereof. HMB may be added to food products comprising a source of amino-nitrogen enriched with large neutral amino acids such as leucine, isoleucine, valine, tyrosine, threonine and phenylalanine and substantially lacking in free amino acids.Type: ApplicationFiled: January 11, 2012Publication date: July 26, 2012Applicant: ABBOTT LABORATORIESInventors: Jeffrey H. Baxter, Anne C. Voss, Pradip Mukerji
-
Publication number: 20120189709Abstract: Disclosed are methods of treating an individual having a condition characterized by an imbalance in type 1 and type 2 cytokine production, wherein the method comprises administering to the individual an amount of ?-hydroxy-?-methylbutyrate (HMB) effective to modulate or otherwise cause an increase in the ratio of type 1 to type 2 cytokines, including an increase in the ratio of type 1 to type 2 cytokines without a corresponding increase in type 2 cytokine levels. Also disclosed are methods of using HMB to treat asthma and allergies. The methods of the present invention are based upon the discovery that HMB modulates cytokine production, most typically by increasing type 1 cytokines without a corresponding increase in type 2 cytokines.Type: ApplicationFiled: January 11, 2012Publication date: July 26, 2012Applicant: ABBOTT LABORATORIESInventors: Debra L. Thomas, Pradip Mukerji
-
Publication number: 20120189716Abstract: The present invention relates to methods for the prevention and treatment of chronic inflammatory diseases, cancer, and involuntary weight loss. In the practice of the present invention patients are enterally administered HMB alone or alternatively in combination with eicosapentaenoic (20:5 ?-3), FOS, carnitine and mixtures thereof. HMB may be added to food products comprising a source of amino-nitrogen enriched with large neutral amino acids such as leucine, isoleucine, valine, tyrosine, threonine and phenylalanine and substantially lacking in free amino acids.Type: ApplicationFiled: January 11, 2012Publication date: July 26, 2012Applicant: ABBOTT LABORATORIESInventors: Jeffrey H. Baxter, Anne C. Voss, Pradip Mukerji
-
Publication number: 20120189715Abstract: The present invention relates to methods for the prevention and treatment of chronic inflammatory diseases, cancer, and involuntary weight loss. In the practice of the present invention patients are enterally administered HMB alone or alternatively in combination with eicosapentaenoic (20:5 ?-3), FOS, carnitine and mixtures thereof. HMB may be added to food products comprising a source of amino-nitrogen enriched with large neutral amino acids such as leucine, isoleucine, valine, tyrosine, threonine and phenylalanine and substantially lacking in free amino acids.Type: ApplicationFiled: January 11, 2012Publication date: July 26, 2012Applicant: ABBOTT LABORATORIESInventors: Jeffrey H. Baxter, Anne C. Voss, Pradip Mukerji
-
Publication number: 20120189717Abstract: The present invention relates to methods for the prevention and treatment of chronic inflammatory diseases, cancer, and involuntary weight loss. In the practice of the present invention patients are enterally administered HMB alone or alternatively in combination with eicosapentaenoic (20:5 ?-3), FOS, carnitine and mixtures thereof. HMB may be added to food products comprising a source of amino-nitrogen enriched with large neutral amino acids such as leucine, isoleucine, valine, tyrosine, threonine and phenylalanine and subtantially lacking in free amino acids.Type: ApplicationFiled: January 11, 2012Publication date: July 26, 2012Applicant: ABBOTT LABORATORIESInventors: Jeffrey H. Baxter, Anne C. Voss, Pradip Mukerji, Michael J. Tisdale
-
Publication number: 20120177744Abstract: Disclosed are methods of treating an individual having a condition characterized by an imbalance in type 1 and type 2 cytokine production, wherein the method comprises administering to the individual an amount of ?-hydroxy-?-methylbutyrate (HMB) effective to modulate or otherwise cause an increase in the ratio of type 1 to type 2 cytokines, including an increase in the ratio of type 1 to type 2 cytokines without a corresponding increase in type 2 cytokine levels. Also disclosed are methods of using HMB to treat asthma and allergies. The methods of the present invention are based upon the discovery that HMB modulates cytokine production, most typically by increasing type 1 cytokines without a corresponding increase in type 2 cytokines.Type: ApplicationFiled: January 11, 2012Publication date: July 12, 2012Applicant: ABBOTT LABORATORIESInventors: Debra L. Thomas, Pradip Mukerji